{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008673","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.073059+00:00","generated_at":"2026-06-15T09:55:58.785990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202","bullets":["Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.","Phase 2 trial started for XTX202 (tumor-activated IL-2) in advanced RCC and melanoma.","R&D expenses $16.1M, up from $14.9M, driven by clinical and manufacturing activities.","Net loss $22.6M vs $21.4M in Q1 2022.","Plan to report preliminary Phase 1 data for XTX101 (anti-CTLA-4) in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008673","json":"https://secwatch.observer/filing/0001558370-23-008673.json","markdown":"https://secwatch.observer/filing/0001558370-23-008673.md","text":"https://secwatch.observer/filing/0001558370-23-008673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/xlo-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:55:58.785990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"609f747d767711d2745776d2ea409e2cd53781d2","claim":"Xilio Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income $22.6 million.","evidence_excerpt":"Xilio Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$22.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}